Rein Therapeutics(RNTX)

Focus: Rein Therapeutics is a public biotechnology company focused on perpetually active peptides across nephrology, respiratory, and oncology indications. With 5,000+ employees and headquarters in Austin, TX, it operates as a mid-cap biotech with early-stage clinical programs.

Nephrology Respiratory Oncology

Profile data last refreshed 16h ago · AI intelligence enriched 3w ago

Funding Stage

PUBLIC

Employees

5000+

Open Jobs

About Rein Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Rein Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

4/9 — Basic

Company HealthStrong

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$0K

Pipeline & Clinical Trials

Impact of the Routine Collection of Symptoms on Quality of Life in Dialysis Patients

Patients Reported Outcomes

N/A

Clinical Trials (1)

NCT05154708Impact of the Routine Collection of Symptoms on Quality of Life in Dialysis Patients

N/A

Help build intelligence for Rein Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Specialized focus on perpetually active peptide platform—an emerging modality offering differentiation in under-served therapeutic areas.
Public company status with 5,000+ employees provides stable infrastructure, equity upside, and career mobility across functions.
Presence in high-need areas (nephrology, IPF, renal cancer) with clear unmet medical needs and meaningful clinical potential.

Watch Out For

Severe financial stress: FY2025 R&D spending tripled to $14M with net losses of $62.9M and only $17M cash, raising questions about runway.
Pipeline maturity concerns: only 4 active trials (2 Phase 1, 2 Phase 2, zero Phase 3 programs), with no marketed products and no clear near-term revenue catalysts.
Zero active job openings currently posted despite 5,000+ headcount—suggests hiring freeze or major restructuring risk.

Generated by Claude from Rein Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

No systematic monitoring of symptoms

End Stage Renal Disease

N/A

Clinical Trials (1)

NCT06257134Impact on Quality of Life of Symptoms Routine E-monitoring Among Dialysis Patients.

N/A

Daily hemodialysis at low dialysate flow

End Stage Renal Disease

N/A

Clinical Trials (1)

NCT01845012Evaluation of Daily HemoDialysis at Low Dialysate Flow in Patients Previously Treated With Conventional Hemodialysis

N/A